ArticleScientific reports2026
Bulk and single-cell transcriptomics reveal prognostic signatures of phosphoinositide metabolism in lung adenocarcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Lung adenocarcinoma (LUAD) is one of the most severe malignant tumors. Phosphoinositides metabolism (PIM) plays an important role in maintaining the normal life activities of the organism and regulating tumor development. This study aimed to comprehensively investigate the association between LUAD and PIM. Data on LUAD and PIM-related genes (PIM-RGs) were sourced from public databases. Differential expression, univariate Cox regression analyses, and machine learning were conducted to identify prognostic genes. A risk model was subsequently developed, and LUAD patients were categorized into a high-risk group (HRG) and a low-risk group (LRG). Independent prognostic factors for LUAD were identified, and a nomogram was constructed. Functional enrichment, tumor microenvironment, mutations, and drug sensitivity analyses were also conducted to investigate the molecular mechanisms underlying LUAD. Additionally, single-cell RNA sequencing (scRNA-seq) data analysis was employed to identify key cells and clarify the dynamics of prognostic genes' expression. Ultimately, prognostic gene expression was investigated in clinical samples. MTMR7, GDPD1, MTMR4, and MTMR10 were recognized as prognostic genes. The risk model and nomogram (incorporating risk score and Stage) had good predictive performance. Notably, LUAD's malignant progression might be closely associated with biological processes including cellular protein synthesis, abnormal activation of neuroactive ligand-receptor interactions, and anti-tumor immune responses. Additionally, there was a general positive correlation between the differentially infiltrated immune cells of HRG and LRG. Moreover, TP53 and TTN had relatively high mutation frequencies in both HRG and LRG, and 142 drugs exhibited differential sensitivity between the 2 groups. Interestingly, epithelial cells were identified as LUAD's key cell type, with prognostic gene expression showing dynamic changes as these cells differentiated. Consistently, compared with the control group, GDPD1 and MTMR4 were upregulated, MTMR10 was downregulated, and MTMR7 showed no statistical difference but a certain upward trend in the LUAD group. This study identified 4 prognostic genes and constructed an effective risk model, providing a new perspective on the treatment of LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.